# Oral Hair-Loss Drug Aces Phase 3 Trial

> Veradermics oral hair-loss drug VDPHL01 meets Phase 3 trial targets, sparking 11% stock surge.
- Title: Oral Hair-Loss Drug Aces Phase 3 Trial · BigGo Finance
- Summary: Veradermics oral hair-loss drug VDPHL01 meets Phase 3 trial targets, sparking 11% stock surge. Veradermics' oral hair-loss drug VDPHL01 achieved key Phase 3…
- Keywords: veradermics, vdpahl01, minoxidil, fda, androgenetic alopecia, phase 3 trial, hair loss treatment, stock market, finance, markets, Oral, Hair-Loss
- Source: BigGo Finance — https://finance.biggo.com/news/8f187633-aef7-454b-ae50-92524d6d3ed9
- Author: BigGo Finance
- Published: 2026-10-19T21:35:12+00:00
- Read time: 2 min
- Topics: veradermics, vdpahl01, minoxidil, fda, androgenetic alopecia, phase 3 trial, hair loss treatment, stock market, finance, markets
## Veradermics Announces Phase 3 Success
U.S. biopharmaceutical company Veradermics announced its extended-release oral minoxidil formulation VDPHL01 met all primary and secondary endpoints in Part A of its registrational Phase 3 study, Study 304.
## Trial Results Show Strong Hair Growth
The trial enrolled 536 men with mild-to-moderate androgenetic alopecia; after six months, the once-daily and twice-daily groups showed mean increases of 28.6 and 36.
## Patient Self-Assessment Improves
The proportion of patients self-reporting 'improved' or 'greatly improved' was 55.7% and 68.7%, respectively, versus 15.0% for placebo.
## Drug Well Tolerated
The drug was generally well tolerated, with no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
## Stock Surges 11% Intraday
The news sent the stock up more than 11% intraday, with Veradermics shares trading at NYSE: MANE.
## Potential First FDA Approval
The company says the drug could become the first FDA-approved non-hormonal oral treatment for androgenetic alopecia in nearly 30 years.
## Competitive Landscape
Cosmo, Pelage, and Eli Lilly-backed Amplifica and Absci are all pursuing this cash-pay medical market.
## Market Potential
Pharmaceutical companies and investors generally believe hair-loss treatment could grow into a lucrative cash-pay medical market, following a path similar to the rapidly expanding weight-loss drug market in recent years.
## Investor Expert Opinion
Jared Holz, a healthcare industry expert at Mizuho Securities, believes hair loss could become the next large consumer medical market, saying competition in the field is 'getting fiercer by the day.'
## Japanese Market Differences
The Japanese Dermatological Association lists topical minoxidil as Recommendation Grade A but oral minoxidil as Grade D, citing systemic side effect risks.
## Market Impact Potential
If VDPHL01 is approved, it could create an opening in brand awareness and prescribing habits and drive the entire category toward oral, extended-release, low-cardiac-risk options.
## Next Steps for Approval
Veradermics has not yet conducted a head-to-head comparison with conventional oral minoxidil, so the drug's real-world advantage remains uncertain.
## Competitor Developments
Cosmo Pharmaceuticals has produced positive results in two Phase 3 trials with 1,465 patients; Pelage Pharmaceuticals has enrolled its first patient in a Phase 2/3 trial.
## Market Access Timeline
Key factors for market success include FDA review timeline, pricing, efficacy comparison data versus generic minoxidil, and launch cadence of competitors.
## Key takeaway

Veradermics' oral hair-loss drug VDPHL01 achieved key Phase 3 trial results, potentially becoming the first FDA-approved non-hormonal oral treatment for hair loss in nearly 30 years.